Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the GLA gene encoding alpha-galactosidase A, leading to accumulation of the lipid globotriaosylceramide (Gb3) in blood vessels, kidneys, heart, and nervous system. Without treatment, it causes progressive kidney failure, stroke, cardiomyopathy, and premature death. Women can also be significantly affected despite being carriers.
What's actually going on in research
Enzyme replacement therapy (ERT) with agalsidase alfa or agalsidase beta has been the standard treatment for decades, reducing Gb3 accumulation and slowing organ damage in many patients. Migalastat, an oral pharmacological chaperone for amenable GLA mutations, is now approved as an alternative for suitable patients. Trials are evaluating next-generation ERT formulations with improved tissue distribution, gene therapy targeting permanent GLA restoration, and substrate reduction therapy to reduce Gb3 production upstream.
Gene therapy
AAV-based and lentiviral gene therapy approaches that restore functional alpha-galactosidase A production are in phase 1/2 trials, with the potential to replace lifelong enzyme infusions with a one-time treatment.
Next-generation ERT
Engineered ERT variants with enhanced receptor targeting, extended half-life, or improved CNS and cardiac penetration are in trials aiming to outperform current enzyme replacement in hard-to-treat manifestations.
Substrate reduction therapy
Small molecules that reduce Gb3 synthesis upstream of the deficient enzyme are in development as oral alternatives or adjuncts to ERT, particularly for manifestations not fully addressed by current therapy.
What to know before you search
Eligibility typically requires confirmed GLA mutation and Fabry disease diagnosis; pharmacological chaperone trials require amenable mutations.
What types of trials are currently open
- Gene therapy trials — AAV and lentiviral gene therapy for permanent GLA restoration in early-phase Fabry disease studies.
- Next-generation ERT trials — Testing engineered enzyme formulations with improved tissue targeting and longer dosing intervals.
- Pharmacological chaperone trials — Evaluating migalastat and newer chaperones across broader mutation spectra in Fabry disease.
- Substrate reduction trials — Studying small molecules reducing Gb3 synthesis as alternatives or complements to ERT.
- Cardiac and renal complication trials — Assessing ERT and novel agents in preventing or reversing Fabry cardiomyopathy and nephropathy.
Recently added Fabry Disease trials
Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
This observational study aims to evaluate myocardial perfusion abnormalities using quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging in patients with hypertrophic cardiomyopathy (HCM) phenotypes, including sarcomeric and non-sarcomeric HCM, Anderson-Fabry disease (AFD), and cardiac amyloidosis. The study will also include first-degree relatives of affected patients and genetic mutation carriers. By comparing myocardial blood flow and perfusion patterns across these different conditions, the study seeks to identify distinctive perfusion signatures that may improve diagnostic differentiation, support risk stratification, and provide insights into the role of ischemia in fibrosis progression, arrhythmias, and long-term outcomes.
Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques
What is this study about? This research is focused on improving the care for people with rare heart muscle diseases, known as rare cardiomyopathies. These are uncommon conditions where the heart muscle becomes stiff, thick, or enlarged, making it harder for the heart to pump blood. Because they are rare, they can be difficult to diagnose and manage. The investigators are testing new, advanced ways of using a heart scan called a Cardiac Magnetic Resonance (CMR). Participants can think of a CMR as a very powerful camera that takes detailed pictures of their heart without using radiation. What is the study trying to learn? Better Diagnosis: The investigators want to see if these new scanning techniques can help us identify these rare heart conditions more clearly and accurately. This means patients could get a correct diagnosis sooner. Personalized Risk Assessment: The investigators want to see if the scan can help us understand the future risk for each patient better. For example, can it help predict which patients are more likely to have a heart rhythm problem or need specific treatments? This helps doctors create a care plan that is tailored just for participants. What does this mean for participants? If participants choose to take part, they will undergo a CMR scan that uses these new techniques. By participating, they will be helping us find better ways to diagnose and care for people with their condition in the future. The goal is to turn uncertainty into clearer, more personalized information for patients and families.
Find Fabry Disease trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.